Application of botulinum toxin in facial paralysis: A review study

Beatriz Brumato Macedo; Rogério Rodrigo Ramos

doi:10.31686/ijier.vol10.iss7.3833

Authors

Beatriz Brumato Macedo Universidade Brasil (UB) https://orcid.org/0000-0003-4801-181X
Rogério Rodrigo Ramos Universidade Brasil (UB) https://orcid.org/0000-0003-1977-4172

DOI:

https://doi.org/10.31686/ijier.vol10.iss7.3833

Keywords:

Facial paralysis, Facial nerve, Botulinum toxin

Abstract

Botulinum toxin (BT) considered a potent substance with high potential in several treatments, has also been gaining space in dental clinics for the treatment of various pathologies, is safe when used in appropriate doses and contraindications are respected. Before starting BT therapy, it is necessary to communicate the patient about all the potentialities and limitations of treatment. The toxin has become an efficient option for the treatment of facial paralysis (FP), a pathology that causes contraction in the facial muscles, causing temporomandibular dysfunction, damage to the process of eating food and liquids, as well as aesthetic constraints, compromising the patient's quality of life. The objective was to present the application of BT as a therapeutic option in FP. This is a review with qualitative data researched in PubMed, VHL, SciELO and LILACS. Seventy-two studies were found, excluding 27 that were outside the inclusion criteria, and 45 studies were selected. It was found that the first step to its use is to analyze the patient, evaluating the facial resuscitation procedure, defining the possibility of reversal or considerable improvement. Subsequently, it is essential to determine the cause of paralysis, its duration and the functional deficits that the patient presents, after establishing the cause, its indication is evaluated. It is essential that an individualized evaluation is always performed, proposing a realistic therapy, and making the patient aware that it is a temporary treatment. The medical literature also shows a positive effect for the use of BT in the treatment of FP, improving the quality of life, especially the patient's self-esteem.

Downloads

Download data is not yet available.

References

Andalécio MM, Andrade RS, Lima LCS, Carvalho TA, Silva IAPS. The use of botulinum toxin in the treatment of peripheral facial palsy. Research, Society and Development, 2021; 10(9): e8510917935. http://dx.doi.org/10.33448/rsd-v10i9.17935 DOI: https://doi.org/10.33448/rsd-v10i9.17935

Barbosa DBM, Brito AS. A utilização da toxina botulínica tipo A para alcançar a estética facial. Revista Terra & Cultura: Cadernos de Ensino e Pesquisa, 2020; 36(70): 75-86. Available from: http://periodicos.unifil.br/index.php/Revistateste/article/view/1354

Oliveira MD, Valadão IF. A utilização da toxina botulínica em odontologia. Rev Assoc Paul Cir Dent, 2014; 68(3): 244. Available from: http://revodonto.bvsalud.org/pdf/apcd/v68n3/a12v68n3.pdf.

Acosta RT, Kelmer F, Oliveira RCG, Oliveira RCG. Uso da toxina botulínica como meio terapêutico para tratamento de assimetria facial causada por hipertrofia do músculo masséter. Uningá Review, 2015; 21: 24-26. Available from: https://revista.uninga.br/uningareviews/article/view/1618

Ferreira VM, Moreira GL, Morales AFP. A utilização da toxina botulínica no tratamento para paralisia facial. Archives of Health Investigation, 2018; 7. Available from: https://www.archhealthinvestigation.com.br/ArcHI/article/view/3828

Adoni T. Paralisia Facial Periférica. Medicinanet, 2008. Available from: https://www.medicinanet.com.br/conteudos/revisoes/1191/paralisia_facial_periferica.htm#:~:text=A%20causa%20mais%20comum%20de,por%20volta%20dos%2040%20anos

Valença MM, Valença LPAA, Lima MCM. Paralisia facial periférica idiopática de Bell: a propósito de 180 pacientes. Arquivos de Neuro-Psiquiatria, 2001; 59(3B): 733-739. https://doi.org/10.1590/S0004-282X2001000500016 DOI: https://doi.org/10.1590/S0004-282X2001000500016

Carvalho VAS, Silva TS, Melo MAMO, et al. Paralisia facial unilateral: aspectos clínicos e principais tratamentos. Braz J Hea Rev, Curitiba, 2020; 3(2): 1761-1765. https://doi.org/10.34119/bjhrv3n2-036 DOI: https://doi.org/10.34119/bjhrv3n2-036

Wenceslau LGC, Sassi FC, Magnani DM, Andrade CRF. Paralisia facial periférica: atividade muscular em diferentes momentos da doença. CoDAS. 2016; 28: 03-09. https://doi.org/10.1590/2317-1782/20162015044. DOI: https://doi.org/10.1590/2317-1782/20162015044

Calais LL, Gomez MVSG, Bento RF, Comerlatti LR. Avaliação funcional da mímica na paralisia facial central por acidente cerebrovascular. Pró-Fono Revista de Atualização Científica, 2005; 17(2): 213-222. https://doi.org/10.1590/S0104-56872005000200010 DOI: https://doi.org/10.1590/S0104-56872005000200010

Tacon KCB, Pereira ECR, Rodrigues PCR, et al. Paralisia facial periférica: perfil dos pacientes atendidos em uma clínica escola. Movimenta, 2019; 12(2): 220-228. Available from: https://www.revista.ueg.br/index.php/movimenta/article/view/8004

Garanhani MR, Cardoso JR, Capelli AMG, Ribeiro MC. Fisioterapia na paralisia facial periférica: estudo retrospectivo. Rev Bras Otorrinolaringol, 2007; 73: 112-115. https://doi.org/10.1590/S0034-72992007000100018 DOI: https://doi.org/10.1590/S0034-72992007000100018

Salles AG. Avaliação do efeito da toxina botulínica no lado são em pacientes com paralisia facial de longa duração. Tese de Doutorado em Ciência, Universidade de São Paulo, São Paulo. 2006. Available from: https://teses.usp.br/teses/disponiveis/5/5158/tde-27082009-152705/pt-br.php

Lang A. History and uses of BOTOX (botulinum toxin type A). Lippincotts Case Manag, 2004; 9(2): 109-12. https://doi.org/10.1097/00129234-200403000-00011. DOI: https://doi.org/10.1097/00129234-200403000-00011

Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain; 2002; 18(6 Suppl): S119-24. https://doi.org/10.1097/00002508-200211001-00002 DOI: https://doi.org/10.1097/00002508-200211001-00002

Yablon S. Toxin neutralizing antibody formation with botulinum toxin type A (BoNTA) treatment in neuromuscular disorders. Neurology, 2005; 64: 1153. DOI: https://doi.org/10.1055/s-2005-919410

Poulain B, Popoff MR, Molgó J. How do the botulism neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. The Botulinum J. 2008; 1: 14-87. https://doi.org/10.1504/TBJ.2008.018951 DOI: https://doi.org/10.1504/TBJ.2008.018951

Colhado OCG, Boeing M, Ortega LB. Toxina botulínica no tratamento da dor. Revista Brasileira de Anestesiologia, 2009; 59(3): 366-381. https://doi.org/10.1590/S0034-70942009000300013 DOI: https://doi.org/10.1590/S0034-70942009000300013

Malizio CJ, Goodnough MC, Johnson EA. Purification of Clostridium botulinum type A neurotoxin. Methods Mol Biol, 2000; 145: 27-39. https://doi.org/10.1385/1-59259-052-7:27 DOI: https://doi.org/10.1385/1-59259-052-7:27

Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon, 2001; 39(12): 1815-20. https://doi.org/10.1016/s0041-0101(01)00101-5 DOI: https://doi.org/10.1016/S0041-0101(01)00101-5

Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol, 2001; 248(Suppl 1): 3-10. https://doi.org/10.1007/pl00007816 DOI: https://doi.org/10.1007/PL00007816

Wohlfarth K, Kampe K, Bigalke H. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov Disord 2004; 19: 65-67. https://doi.org/10.1002/mds.20012 DOI: https://doi.org/10.1002/mds.20012

Truong DD, Stenner A, Reichel G. Current clinical applications of botulinum toxin. Curr Pharm Des. 2009; 15(31): 3671-3680. https://doi.org/10.2174/138161209789271843. DOI: https://doi.org/10.2174/138161209789271843

Ênia JRN, Fernandes JGA, Nascimento F, et al. Toxina botulínica no tratamento da paralisia facial: um tratamento reabilitador minimamente invasivo. Research, Society and Development, 2021; 10(5): e40510515204. http://dx.doi.org/10.33448/rsd-v10i5.15204 DOI: https://doi.org/10.33448/rsd-v10i5.15204

Klein AW. The therapeutic potential of botulinum toxin. Dermatol Surg, 2004; 30(3): 452-455. https://doi.org/10.1111/j.1524-4725.2004.30118.x. DOI: https://doi.org/10.1111/j.1524-4725.2004.30118.x

Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arquivos de Neuro-Psiquiatria, 2005; 63: 180-185. https://doi.org/10.1590/S0004-282X2005000100035. DOI: https://doi.org/10.1590/S0004-282X2005000100035

Domingos MM. O uso da toxina botulínica em doentes com hipercinesia muscular facial contralateral à paralisia facial. Tese de Doutorado em Ciência, Universidade de São Paulo, São Paulo. 2006. Available from: https://www.teses.usp.br/teses/disponiveis/5/5143/tde-17082006-104941/pt-br.php

Cooper L, Lui M, Nduka C. Botulinum toxin treatment for facial palsy: A systematic review. J Plast Reconstr Aesthet Surg, 2017; 70(6): 833-841. https://doi.org/10.1016/j.bjps.2017.01.009 DOI: https://doi.org/10.1016/j.bjps.2017.01.009

Dall’Magro AK, Santo R, Dall’Magro E, et al. Aplicações da toxina botulínica em odontologia. Rev Salusvita, 2015; 34(2): 371-382. Available from: https://secure.unisagrado.edu.br/static/biblioteca/salusvita/salusvita_v34_n2_2015_art_14.pdf

Marciano AM, Aguiar U, Vieira PGM, Magalhães SR. Toxina botulínica e sua aplicação na odontologia. Rev Iniciaç Cient Universidade Vale Rio Verde, 2014; 4: 65-75. Available from: http://periodicos.unincor.br/index.php/iniciacaocientifica/article/view/1554

Serrera-Figallo M-A, Ruiz-de-León-Hernández G, Torres-Lagares D, et al. Use of Botulinum Toxin in Orofacial Clinical Practice. Toxins (Basel), 2020; 12(2): 112. https://doi.org/10.3390/toxins12020112 DOI: https://doi.org/10.3390/toxins12020112

Santos CF, Stresser KCA, Oliveira AMM, et al. Aplicação de toxina botulínica tipo A em paciente com paralisia facial periférica de Bell: relato de caso. RSBO, 2020; 17(2): 221-225. https://doi.org/10.21726/rsbo.v17i2.51 DOI: https://doi.org/10.21726/rsbo.v17i2.51

Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep, 2002; 6(6): 460-469. https://doi.org/10.1007/s11916-002-0065-y DOI: https://doi.org/10.1007/s11916-002-0065-y

Guerra Neto PGS. Toxina botulínica tipo A: ações farmacológicas e riscos do uso nos procedimentos estéticos faciais. 2016. 44 f. Monografia (Especialização em Biomedicina Estética) - Instituto Nacional de Ensino Superior e Pesquisa e Centro de Capacitação Educacional, Recife, 2016. Available from: https://www.ccecursos.com.br/img/resumos/2-toxina-botul-nica-tipo-a-a--es-farmacol-gicas-e-riscos-do-uso-nos-procedimentos-est-ticos-faciais.pdf

Vicente JM. Paralisia de Bell, do diagnóstico ao tratamento: revisão de literatura. Artigo do Centro Universitário São Lucas. Porto Velho-RO 2019. Available from: http://repositorio.saolucas.edu.br:8080/xmlui/bitstream/handle/123456789/3196/Jalisson%20Mendes%20Vicente%20-%20Paralisia%20de%20Bell%2C%20do%20diagn%C3%B3stico%20ao%20tratamento%20revis%C3%A3o%20de%20literatura.pdf?sequence=1&isAllowed=y

Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain, 2002; 18(6suppl): s142-146. https://doi.org/10.1097/00002508-200211001-00005 DOI: https://doi.org/10.1097/00002508-200211001-00005

Alves FC, Souza FB. A utilização da Toxina Botulínica na odontologia. 2016. Dissertação (Graduação em Odontologia) – Curso de Odontologia do UniSL, Centro Universitário São Lucas - UNISL, Porto Velho, 2016. Disponível em: http://repositorio.saolucas.edu.br:8080/xmlui/handle/123456789/1673.

Lima PN, Gusmão RM, Siqueira NCG, Varejão LC. Toxina botulínica como alternativa no tratamento da paralisia facial de Bell: revisão de literatura. BJD, 2020; 6(12): 95667-95681. https://doi.org/10.34117/bjdv6n12-161 DOI: https://doi.org/10.34117/bjdv6n12-161

Ikeda EMG, Oliveira RCG, Oliveira RCG, Freitas KMS. Efeitos da toxina botulínica no tratamento odontológico. Revista Uningá, 2019; 56(S5), 153-162. Available from: https://revista.uninga.br/uninga/article/view/318

Shinn JR, Nwabueze NN, Liping Du L, et al. Treatment patterns and outcomes in botulinum therapy for patients with facial synkinesis. JAMA Facial Plast Surg, 2019; 21(3): 244-251. https://doi.org/10.1001/jamafacial.2018.1962 DOI: https://doi.org/10.1001/jamafacial.2018.1962

do Nascimento Remigio AF, Salles AG, de Faria JCM, Ferreira MC. Comparison of the efficacy of onabotulinumtoxin A and abobotulinumtoxin A at the 1: 3 conversion ratio for the treatment of asymmetry after long-term facial paralysis. Plast Reconstr Surg, 2015; 135: 239-249. https://doi.org/10.1097/PRS.0000000000000800. DOI: https://doi.org/10.1097/PRS.0000000000000800

Mandrini S, Comelli M, Dall'angelo A, et al. Long-term facial improvement after repeated BoNT-A injections and mirror biofeedback exercises for chronic facial synkinesis: a case-series study. Eur J Phys Rehabil Med, 2016; 52(6): 810-818. Available from: https://pubmed.ncbi.nlm.nih.gov/27164539/

Cunha SCN. Paralisia facial periférica diagnóstico e tratamento. Mestrado (Mestrado em Medicina) - Faculdade Ciências da Saúde da Universidade da Beira Interior, Covilhã, 2018. Available from: https://ubibliorum.ubi.pt/bitstream/10400.6/8359/1/6069_12733.pdf

Maio M, Soares MFD. Toxina botulínica em paralisia facial: um tratamento minimamente invasivo para redução da hipercinesia muscular da região perioral contralateral. Arquivos Internacionais de Otorrinolaringologia, 2006; 11: 38-35. Available from: http://arquivosdeorl.org.br/conteudo/pdfForl/401.pdf

Ferreira VM, Moreira GL, Morales AFP. A utilização da toxina botulínica no tratamento para paralisia facial. Archives of Health Investigation, 20019; 7: 1. Available from: https://www.archhealthinvestigation.com.br/ArcHI/article/view/3828.